Belite Bio (BLTE) Total Non-Current Liabilities (2024 - 2025)
Belite Bio's (BLTE) quarterly Total Non-Current Liabilities came in at $188000.0 in Q4 2025, down 27.97% year-on-year from $261000.0 in Q4 2024, and down 97.74% quarter-over-quarter from $8.3 million in Q3 2025.
Belite Bio (BLTE) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Belite Bio's Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $188000.0 for Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities fell 27.97% year-over-year to $188000.0 in Q4 2025; TTM through Dec 2025 was $188000.0, a 27.97% decrease from a year earlier, with the FY2025 full-year figure at $188000.0, down 27.97% from the prior year.
- Total Non-Current Liabilities retreated to $188000.0 in Q4 2025 per BLTE's latest filing, from $8.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $8.3 million in Q3 2025 and bottomed at $188000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 746.94 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 4.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 188,000.00 |
| Sep 30, 2025 | 8.30 Mn |
| Dec 31, 2024 | 261,000.00 |